BeiGene
Presença
BeiGene é uma das ...
BeiGene é uma empresa listada sob o símbolo 6160 (HK).
BeiGene tem presença direta em 2 países.
Eles estão dentro:
- Biotecnologia67%
- Farmacêutica33%
Executivos
Veja o organograma con seus 69 executivos principais
Biografias mais buscadas da BeiGene
- John Oyler, Chairman and Chief Executive Officer
- Corsee Sanders, Director
- Ranjeev Krishana, Director
Recentes movimentos de executivos em BeiGene
- Thomas Malley, Non-Executive Independent Director, deixou a Companhia (Notícia publicada em 24 de janeiro de 2024).
- Olivier Brandicour, ingressou na Companhia como Director (Notícia publicada em 24 de janeiro de 2024).
Criar um alerta
para seguir os movimentos de executivos da BeiGene.
Farmacêutica
BeiGene possui 1.865 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
- Frontier Medicines acaba de anunciar uma arrecadação de fundos de 80 milhões de dólares. (publicado em 27 de fevereiro de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de BeiGene
- Bringing Light to The Darkness of Cancer: BeiGene Named National Partner of Survivorship and Hope for The Leukemia & Lymphoma Society’s Light The Night – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFil
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene to Present at Upcoming Investor Conferences – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results – NASDAQ (US) WebsiteCookies ButtonBack ButtonSearch IconFilter Icon
- View more press releases Close
Redes sociais sobre BeiGene
- BeiGene na Wikipedia, Google News e Yahoo Finance
- BeiGene na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo John Oyler 
Ligue para a BeiGene em +86 105...
